Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: A substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycemia in Diabetes (RECORD) study

Diabetes Care

Volumn 34, Issue 6, 2011, Pages 1394-1396

  MacDonald, Michael R ^a   Petrie, Mark C ^a   Home, Philip D ^b   Komajda, Michel ^c   Jones, Nigel P ^d   Beck Nielsen, Henning ^e   Gomis, Ramon ^f   Hanefeld, Markolf ^g   Pocock, Stuart J ^h   Curtis, Paula S ^d   McMurray, John J V ⁱ  

^a GOLDEN JUBILEE NATIONAL HOSPITAL   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

^c PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^d GLAXOSMITHKLINE   (United Kingdom)

^e Department of Endocrinology and Metabolism ^*  (Denmark)

^f UNIVERSITY OF BARCELONA   (Spain)

^g UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^h LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁱ UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ROSIGLITAZONE;

ARTICLE; CARDIOVASCULAR RISK; ELECTROCARDIOGRAM; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; Q WAVE MYOCARDIAL INFARCTION; RETROSPECTIVE STUDY;

DIABETES MELLITUS, TYPE 2; INCIDENCE; MYOCARDIAL INFARCTION; PREVALENCE; RETROSPECTIVE STUDIES; THIAZOLIDINEDIONES;

EID: 80051964352     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc10-2398     Document Type: Article

References (12)

1. Sheifer S.E., Gersh B.J., Yanez N.D. 3rd, Ades P.A., Burke G.L., Manolio T.A. Prevalence, predisposing factors, and prognosis of clinically unrecognized myocardial infarction in the elderly. J Am Coll Cardiol 2000;35:119-126 (Pubitemid 30061269)
2. Sigurdsson E., Thorgeirsson G., Sigvaldason H., Sigfusson N. Unrecognized myocardial infarction: Epidemiology, clinical characteristics, and the prognostic role of angina pectoris. The Reykjavik Study. Ann Intern Med 1995;122:96-102
3. Yano K., MacLean C.J. The incidence and prognosis of unrecognized myocardial infarction in the Honolulu, Hawaii, Heart Program. Arch Intern Med 1989;149:1528-1532 (Pubitemid 19177624)
4. Home P.D., Pocock S.J., Beck-Nielsen H., et al. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): Study design and protocol. Diabetologia 2005;48:1726-1735 (Pubitemid 41317825)
5. Aguilar D., Goldhaber S.Z., Gans D.J., et al.; Collaborative Study Group. Clinically unrecognized Q-wave myocardial infarction in patients with diabetes mellitus, systemic hypertension, and nephropathy. Am J Cardiol 2004;94:337-339 (Pubitemid 38962699)
6. Boland L.L., Folsom A.R., Sorlie P.D., et al. Occurrence of unrecognized myocardial infarction in subjects aged 45 to 65 years (the ARIC study). Am J Cardiol 2002;90:927-931 (Pubitemid 35232613)
7. Davis T.M., Fortun P., Mulder J., Davis W.A., Bruce D.G.; Fremantle Diabetes Study. Silent myocardial infarction and its prognosis in a community-based cohort of Type 2 diabetic patients: The Fremantle Diabetes Study. Diabetologia 2004;47:395-399 (Pubitemid 38491234)
8. Jónsdóttir L.S., Sigfusson N., Sigvaldason H., Thorgeirsson G. Incidence and prevalence of recognised and unrecognised myocardial infarction in women. The Reykjavik Study. Eur Heart J 1998;19:1011-1018 (Pubitemid 28321380)
9. Nadelmann J., Frishman W.H., Ooi W.L., et al. Prevalence, incidence and prognosis of recognized and unrecognized myocardial infarction in persons aged 75 years or older: The Bronx Aging Study. Am J Cardiol 1990;66:533-537 (Pubitemid 20292507)
10. Dormandy J.A., Charbonnel B., Eckland D.J., et al.; PROactive investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial InmacroVascular Events): A randomised controlled trial. Lancet 2005;366:1279-1289 (Pubitemid 41416583)
11. Burgess D.C., Hunt D., Li L., et al. Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: An analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Eur Heart J 2010;31:92-99
12. Ammar K.A., Kors J.A., Yawn B.P., Rodeheffer R.J. Defining unrecognized myocardial infarction: A call for standardized electrocardiographic diagnostic criteria. Am Heart J 2004;148:277-284 (Pubitemid 39092792)